Sepúlveda R, Soto DR, Mercado U

Language: Spanish
References: 12
Page: 753-759
PDF size: 207.20 Kb.

ABSTRACT

Objective: To compare the clinical presentation and 12-month follow-up of seronegative and seropositive rheumatoid arthritis patients who met 2010 ACR/EULAR criteria.
Materials and Methods: A retrospective observational study was done including patients with early rheumatoid arthritis who were grouped in seropositive rheumatoid arthritis to antibodies against citrullinated proteins-peptide (ACPA) with or without rheumatoid factor and rheumatoid arthritis patients without these autoantibodies. Follow-up was carried out at 12 months with clinical disease activity index, health assessment questionnaire, number of swollen joints and percentage of remission.
Results: There were included 313 patients: 253 had seropositive rheumatoid arthritis and 60 seronegative rheumatoid arthritis. Of these, 21 patients with less than 10 swollen joints were excluded. There was no difference in the age between both groups; 95% of seronegative rheumatoid arthritis and 67% of seropositive rheumatoid arthritis patients presented severe clinical disease activity index (p = 0006). There was a trend in severe disability (p = 0.06) and a greater number of swollen joints in seronegative rheumatoid arthritis patients. The 12-month followup showed no difference in the percentage of remission, disability and number of swollen joints between groups.
Conclusions: Clinically the presentation of seronegative rheumatoid arthritis is severe. In the absence of autoantibodies, seronegative patients require more than 10 swollen joints to meet the 2010 ACR/EULAR criteria.

REFERENCES

1. Daha NA, Toes REM. Are ACPA-positive and ACPA-negativeRA the same disease? Nat Rev Rheumatol 2011; 7: 202-203.doi: 10.1038/nrrheum.2011.28.

2. Ajeganova S, Huizinga TWJ. Seronegative and seropositiveRA: alike but different? Nat Rev Rheumatol 2014; 11: 8-9.https://doi.org/10.1038/nrrheum.2014.194.

3. Padyukov LL, Mark Seielstad M, Ong RTH, Bo Ding B, RönnelidJ, Seddighzadeh, M, et al. A genome-wide associationstudy suggests contrasting associations in ACPA-positiveversus ACPA-negative rheumatoid arthritis. Ann. Rheum.Dis 2011; 70: 259-265. doi: 10.1136/ard.2009.126821.

4. Avouac J, Gossec L, Dougados M. Diagnostic and predictivevalue of anti-cyclic citrullinated protein antibodiesin rheumatoid arthritis: a systematic literature review.Ann Rheum Dis 2006; 65: 845-851. doi: 10.1136/ard.2006.051391.

5. Van der Helm-van Mill AH, Huizinga TW. Advances in thegenetics of rheumatoid arthritis point to subclassificationinto distinct disease subsets. Arthritis Res Ther 2008; 10:205. doi: 10.1186/ar2384.

6. Shi R, Knevel P, Siwannalai MP, van der Linden GM, JanssenPA, van Veelen, et al. Autoantibodies recognizingcarbamylated proteins are present in sera of patients withrheumatoid arthritis and predict joint damage. Proc NatlAcad Sci. USA 2011;108:17372-77.

7. Truchetet ME, Dublanc S, Bamtchte T, Vittecoq O, MarietteX, Richez C et al. Association of the presence of anticarbamylatedprotein antibodies in early arthritis witha poorer clinical and radiologic outcome: data from theFrench ESPOIR cohort. Arthritis Rheum 2017; 69: 2292-2302. doi: 10.1002/art.40237.

8. Barra L, Pope JE, Orav JE Boire G, Haraoui B, Hitchon C etal. Prognosis of seronegative patients in a large prospectivecohort of patients with early inflammatory arthritis. JRheumatol 2014; 4: 2361-9. DOI: https://doi.org/10.3899/jrheum.140082

9. Nordberg LB, Liligraven S, Lie E, Aga AB, Olsen IC, HammerHB, Uhlig T, Jonsson K, et al. Patients with seronegative RAhave more inflammatory activity compared with patientswith seropositive in an inception cohort of DMARD-naïvepatients classified according to the 2010 ACR/EULARcriteria. Ann Rheum Dis 2017; 76: 341-45. doi: 10.1136/annrheumdis-2015-208873.

10. Choi ST, Lee KH. Clinical management of seronegativeand seropositive rheumatoid arthritis: A comparativestudy. PLoS ONE 2018, 13: 1-10. doi: 10.1371/journal.pone.0195550.

11. Mouterde G, Cheval NR, Lukas C, Daien C, Saraux A, DieudeP, et al. Outcome of patients with early arthritis withoutrheumatoid factor and ACPA and predictors of rheumatoidarthritis in the ESPOIR cohort. Arthritis Res Ther 2019; 21:140. doi: 10.1186/s13075-019-1909-8.

12. Aletaha D, Neogi T, Silman AJ, Funovits J, et al. 2010 rheumatoidarthritis classification criteria: an American Collegeof Rheumatology/European League Against Rheumatismcollaborative initiative. Ann Rheum 2010; 69: 2569-81. doi:10.1002/art.27584.